| Autor: |
Viaggi, Valentina, Pini, Beatrice, Tonolo, Silvia, Luzzaro, Francesco, Principe, Luigi |
| Zdroj: |
Journal of Chemotherapy; May 2019, Vol. 31 Issue: 4 p195-201, 7p |
| Abstrakt: |
Resistance to carbapenems in Enterobacteriaceaeis a serious concern for public health. Alternative treatment options involving carbapenem-sparing regimen for patients with serious infections caused by multidrug-resistant Enterobacteriaceaeare urgently needed. Ceftazidime/avibactam (CZA) is a new combination of a third generation cephalosporin and a non-β-lactam β-lactamase inhibitor, in which avibactam is capable to expand the ceftazidime activity also against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. To date, no data exist regarding the activity of CZA against strains isolated in the Italian context, which is known as endemic for ESBL producers. The aim of this study was to evaluate the in vitroactivity of CZA, in comparison to ceftazidime (CAZ), against 90 ESBL-producing Escherichia coliand Klebsiella pneumoniaeisolates, collected from blood and urine samples at our Institute. Thus, avibactam has been able to restore the activity of CAZ in all cases, suggesting the potential use of CZA as a carbapenem-sparing model, especially when limited therapeutic options exist. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
